Baxter International Inc. (NYSE:BAX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
On May8, 2018, the Company held its annual meeting of stockholders. Of the 537,807,098 shares outstanding and entitled to vote, 469,522,247 shares were represented at the meeting, constituting a quorum of approximately 87%. The following is a summary of the matters voted on at the meeting.
(a) | The twelve nominees for director were elected as follows: |
Nominee |
For | Against | Abstain | BrokerNon-Votes |
José (Joe) Almeida |
388,951,661 | 22,560,426 | 6,750,005 | 51,260,155 |
Thomas F. Chen |
416,583,022 | 1,299,256 | 379,814 | 51,260,155 |
John D. Forsyth |
396,778,712 | 21,098,610 | 384,770 | 51,260,155 |
James R. Gavin III |
390,766,514 | 27,084,080 | 411,498 | 51,260,155 |
Peter S. Hellman |
400,859,399 | 17,011,473 | 391,220 | 51,260,155 |
Munib Islam |
416,645,237 | 1,218,043 | 398,812 | 51,260,155 |
Michael F. Mahoney |
410,127,410 | 7,747,883 | 386,799 | 51,260,155 |
Stephen N. Oesterle |
412,760,210 | 5,117,360 | 384,522 | 51,260,155 |
Carole J. Shapazian |
402,564,331 | 15,332,274 | 365,487 | 51,260,155 |
Cathy R. Smith |
417,077,161 | 841,394 | 343,537 | 51,260,155 |
Thomas T. Stallkamp |
397,131,910 | 20,748,720 | 381,462 | 51,260,155 |
Albert P.L. Stroucken |
401,293,991 | 16,598,115 | 369,986 | 51,260,155 |
(b) | By the following vote, stockholders approved, on an advisory basis, the 2017 compensation paid to the Company’s named executive officers: |
For |
Against |
Abstain |
BrokerNon-Votes |
389,739,101 | 26,455,457 | 2,067,534 | 51,260,155 |
(c) | The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2018 was ratified by the following vote: |
For |
Against |
Abstain |
456,821,313 | 12,158,628 | 542,306 |
(d) | By the following vote, stockholders did not approve the stockholder proposal relating to an independent board chairman: |
For |
Against |
Abstain |
BrokerNon-Votes |
103,449,958 | 300,851,330 | 13,960,804 | 51,260,155 |
(e) | By the following vote, stockholders did not approve the stockholder proposal relating to the right to act by written consent: |
For |
Against |
Abstain |
BrokerNon-Votes |
173,988,958 | 242,840,111 | 1,433,023 | 51,260,155 |
About Baxter International Inc. (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.